rs121908644
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM2PM5PP3PP5_Very_Strong
The NM_054012.4(ASS1):c.256C>T(p.Arg86Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000403 in 1,612,422 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R86H) has been classified as Pathogenic.
Frequency
Consequence
NM_054012.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ASS1 | NM_054012.4 | c.256C>T | p.Arg86Cys | missense_variant | 4/15 | ENST00000352480.10 | NP_446464.1 | |
ASS1 | NM_000050.4 | c.256C>T | p.Arg86Cys | missense_variant | 5/16 | NP_000041.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ASS1 | ENST00000352480.10 | c.256C>T | p.Arg86Cys | missense_variant | 4/15 | 1 | NM_054012.4 | ENSP00000253004 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152170Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000438 AC: 11AN: 250884Hom.: 0 AF XY: 0.0000516 AC XY: 7AN XY: 135676
GnomAD4 exome AF: 0.0000431 AC: 63AN: 1460252Hom.: 0 Cov.: 32 AF XY: 0.0000344 AC XY: 25AN XY: 726454
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152170Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74340
ClinVar
Submissions by phenotype
Citrullinemia type I Pathogenic:4
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 1991 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 05, 2024 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 15, 2020 | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Counsyl | Jun 27, 2017 | - - |
Citrullinemia Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 07, 2023 | Variant summary: ASS1 c.256C>T (p.Arg86Cys) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.4e-05 in 250884 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in ASS1 causing Citrullinemia Type I (4.4e-05 vs 0.0041), allowing no conclusion about variant significance. c.256C>T has been reported in the literature in multiple homozygous patients (Martin-Hernandez_2014, Zielonka_2019), and in at least one compound heterozygous individual in trans from a pathogenic variant (Kobayashi_1991), with Citrullinemia Type I and associated phenotypes. These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function showing residual enzymatic ASS1 activity in a homozygous indivdual was about 5% of wildtype (Zielonka_2019) . Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic (n=3) and likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 86 of the ASS1 protein (p.Arg86Cys). This variant is present in population databases (rs121908644, gnomAD 0.02%). This missense change has been observed in individual(s) with citrullinemia type 1 (PMID: 1943692, 25433810). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 6332). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ASS1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects ASS1 function (PMID: 1943692). This variant disrupts the p.Arg86 amino acid residue in ASS1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12815590). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 17, 2023 | Published functional studies demonstrate a damaging effect as residual enzymatic activity was reduced to about 20% of wild-type (Zielonka et al., 2019); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24772957, 24508627, 22494545, 12815590, 1943692, 25433810, 19006241, 7977368, 28111830, 31589614, 32778825, 31469252) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at